期刊
BIOCHEMICAL PHARMACOLOGY
卷 173, 期 -, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2019.113698
关键词
Cancer; Histone acetylation; Targeted treatment; Personalized medicine
资金
- Televie Luxemburg
- Recherche Cancer et Sang foundation
- Recherches Scientifiques Luxembourg
- Een Haerz fir kriibskrank Kanner
- Action LIONS Vaincre le Cancer
- Televie Luxembourg
- National Research Foundation (NRF) [019R1A2C1009231]
- MEST of Korea for Tumor Microenvironment Global Core Research Center (GCRC) [2011-0030001]
- Brain Korea (BK21) PLUS program at Seoul National University [370C-20160062]
- Creative-Pioneering Researchers Program at Seoul National University [370C-20160062]
Chronic myeloid leukemia (CML) is a hematological disorder caused by the oncogenic BCR-ABL fusion protein in more than 90% of patients. Despite the striking improvements in the management of CML patients since the introduction of tyrosine kinase inhibitors (TKis), the appearance of TKi resistance and side effects lead to treatment failure, justifying the need of novel therapeutic approaches. Histone deacetylase inhibitors (HDACis), able to modulate gene expression patterns and important cellular signaling pathways through the regulation of the acetylation status of both histone and non-histone protein targets, have been reported to display promising anti-leukemic properties alone or in combination with TKis. This review summarizes pre-clinical and clinical studies that investigated the mechanisms underlying the anticancer potential of HDACis and discusses the rationale for a combination of HDACis with TKis as a therapeutic option in CML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据